SCHEMBL1933116

SCHEMBL1933116

Brc1ccc2c(c1)OC(c1ccccn1)CC2

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ESR1 P03372 1/20 0.40
ESR2 Q92731 1/20 0.40
HTR1A P08908 3/20 0.35
HTR1D P28221 3/20 0.35
AVPR1A P37288 2/20 0.33
DDB1 Q16531 1/20 0.33
CRBN Q96SW2 1/20 0.33
DRD2 P14416 2/20 0.33
DRD4 P21917 2/20 0.33
DRD3 P35462 2/20 0.33
FFAR1 O14842 2/20 0.33
MAPT P10636 1/20 0.33
TSHR P16473 1/20 0.33
DRD1 P21728 1/20 0.33
DRD5 P21918 1/20 0.33
KDM4E B2RXH2 1/20 0.33
ALDH1A1 P00352 1/20 0.33
AHR P35869 1/20 0.33
SLC8A1 P32418 1/20 0.32
SNRNP200 O75643 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12556044 0.84 ESR1 (0.40) ESR1ESR2DRD2DRD4DRD3
SCHEMBL6296267 0.84 ESR2 (0.59) ESR1ESR2DRD2DRD4DRD3
SCHEMBL6292853 0.83 HTR1A (0.45) HTR1AHTR1DDDB1CRBNKDM4E
SCHEMBL13820745 0.81 FFAR1 (0.42) ESR1ESR2FFAR1
SCHEMBL1934071 0.79 ESR1 (0.55) ESR1ESR2DRD2DRD4DRD3
SCHEMBL1933038 0.79 ESR1 (0.55) ESR1ESR2DRD2DRD4DRD3
SCHEMBL1933040 0.79 ESR1 (0.55) ESR1ESR2DRD2DRD4DRD3
SCHEMBL16857321 0.78 SNRNP200 (0.37) ESR1ESR2HTR1AHTR1DDDB1
SCHEMBL13720329 0.76 LPL (0.35) ESR1ESR2DDB1CRBNFFAR1
SCHEMBL6291943 0.76 ESR1 (0.59) ESR1ESR2KDM4EALDH1A1SLC8A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120289501-A1 Benzene-fused 6-membered oxygen-containing heterocyclic derivatives of bicyclic heteroaryls NOVARTIS AG (CH) 2012-11-15 US disclosed
EP-2504339-A1 BENZENE-FUSED 6-MEMBERED OXYGEN-CONTAINING HETEROCYCLIC DERIVATIVES OF BICYCLIC HETEROARYLS Novartis AG (CH) 2012-10-03 EP disclosed
CN-102712648-A Benzene-fused 6-membered oxygen-containing heterocyclic derivatives of bicyclic heteroaryls NOVARTIS AG 2012-10-03 CN disclosed
WO-2011064211-A1 BENZENE-FUSED 6-MEMBERED OXYGEN-CONTAINING HETEROCYCLIC DERIVATIVES OF BICYCLIC HETEROARYLS NOVARTIS AG (CH) 2011-06-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120289501-A1 Benzene-fused 6-membered oxygen-containing heterocyclic derivatives of bicyclic heteroaryls CYP1B1, CYP11B2, CCNI ESR1 561/4885ESR2 290/4885HTR1A 2959/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.